MARKET

ONVO

ONVO

Organovo Holdings
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.910
+0.120
+4.30%
Closed 16:00 01/24 EST
OPEN
2.750
PREV CLOSE
2.790
HIGH
2.960
LOW
2.560
VOLUME
114.01K
TURNOVER
--
52 WEEK HIGH
23.92
52 WEEK LOW
2.560
MARKET CAP
25.33M
P/E (TTM)
-2.0799
1D
5D
1M
3M
1Y
5Y
15 Worst Stock Picks of Cathie Wood
In this article, we discuss the 15 worst stock picks of Cathie Wood. If you want to skip our detailed analysis of these stocks, go directly to the 5 Worst Stock Picks of Cathie Wood. Cathie Wood, the chief ARK Investment Management, is often hailed as the ...
Insider Monkey · 3d ago
61 Biggest Movers From Yesterday
Gainers Genprex, Inc. (NASDAQ: GNPX) shares surged 167.2% to settle at $3.50 on Monday. The FDA granted Fast Track Designation for Genprex’s lead drug candidate, Reqorsa Immunogene combination therapy.
Benzinga · 01/04 10:06
Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 12/30/2021 14:24
Organovo Holdings Says On Track To Establish Human 3D Model In Inflammatory Bowel Disease In 2022
Organovo Holdings, Inc. (NASDAQ:ONVO), today provided a business overview and progress update, and announced it is on track to establish its first models of inflammatory bowel disease in 2022 using its 3D bioprinting and
Benzinga · 11/30/2021 13:10
50 Biggest Movers From Yesterday
Gainers
Benzinga · 11/30/2021 09:45
33 Stocks Moving In Monday's Mid-Day Session
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares jumped 116.4% to $86.13 after the company announced positive topline results from the GEM-3 Phase 3 trial of investigational beremagene geperpavec (B-VEC, Vyjuvek) for dystrophic Epidermolysis Bullosa (dy...
Benzinga · 11/29/2021 17:00
Organovo Shares Up 26%; Recent Seeking Alpha Blog Post From Contributor 'Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside'
https://seekingalpha.com/article/4431909-organovo-new-strategy-targetting-internal-pipeline-development-offers-upside
Benzinga · 11/19/2021 21:16
BRIEF-Organovo Holdings Inc - CFO Jonathan Lieber Notified Of His Intent To Resign, From His Part-Time Role To Pursue A Full-Time Opportunity
reuters.com · 10/06/2021 21:08
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONVO. Analyze the recent business situations of Organovo Holdings through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ONVO stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
High3.000
Average3.000
Low3.000
Current 2.910
EPS
Actual
Estimate
-0.32-0.24-0.16-0.08
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2020
Institutional Holdings
Institutions: 125
Institutional Holdings: 5.10M
% Owned: 58.59%
Shares Outstanding: 8.71M
TypeInstitutionsShares
Increased
8
22.30K
New
3
38.81K
Decreased
8
103.81K
Sold Out
9
30.35K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
-0.55%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Keith Murphy
President/Chief Financial Officer
Thomas Hess
Chief Scientific Officer
Jeffrey Miner
General Counsel/Secretary
Thomas Jurgensen
Independent Director
Douglas Cohen
Independent Director
David Gobel
Independent Director
Alison Milhous
Independent Director
Adam Stern
No Data
About ONVO
Organovo Holdings, Inc. is an early stage biotechnology company. The Company is focused on building high fidelity, three-dimensional (3D) tissues that recapitulate key aspects of human disease. The Company is targeting the intestine and has ongoing 3D tissue developments in Ulcerative colitis (UC) and Crohn's disease (CD). The Company uses its platform technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. NovoGen Bioprinters can dispense pure hydrogel formulations and also serve as important components of company's tissue prototyping and manufacturing platform. The Company also intends to use its bioprinting platform as well as 3D technologies to treat its target diseases.

Webull offers kinds of Organovo Holdings Inc stock information, including NASDAQ:ONVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONVO stock methods without spending real money on the virtual paper trading platform.